Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

Andrew Blauvelt, Nianwen Shi, Russel Burge, Bilal Atiya, Baojin Zhu, Najwa Somani, Terri Ridenour, Carolyn R. Lew, Nicole M. Zimmerman and Mwangi J. Murage ()
Additional contact information
Andrew Blauvelt: Oregon Medical Research Center
Nianwen Shi: IBM Watson Health
Russel Burge: Eli Lilly and Company
Bilal Atiya: Eli Lilly and Company
Baojin Zhu: Eli Lilly and Company
Najwa Somani: Eli Lilly and Company
Terri Ridenour: Eli Lilly and Company
Carolyn R. Lew: IBM Watson Health
Nicole M. Zimmerman: IBM Watson Health
Mwangi J. Murage: Eli Lilly and Company

PharmacoEconomics - Open, 2022, vol. 6, issue 6, No 9, 880 pages

Abstract: Abstract Objective The aim of this study was to compare healthcare costs between ixekizumab (IXE)-treated and secukinumab (SEC)-treated patients with psoriasis over a 24-month follow-up period in the United States. Methods Patients with psoriasis diagnosis were identified from IBM Watson Health MarketScan® Research Databases; those with one or more claim for index drug (IXE or SEC) between March 1, 2016 and October 31, 2019 were included. Included patients were ≥ 18 years old and had continuous enrollment with medical and pharmacy benefits ≥ 6 months before and ≥ 24 months after index date. Patients were classified as IXE or SEC users based on drug received at index. Per patient per month (PPPM) all-cause, psoriasis-related, and index drug costs for IXE and SEC users were estimated over 24 months of follow-up. Institute for Clinical and Economic Review (ICER) discount factors were applied to adjust pharmacy costs. Index drug costs were additionally adjusted for adherence. Inverse probability of treatment weighting was used to address cohort imbalances. Chi-square/t tests were used to compare IXE versus SEC users; p value

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-022-00365-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:6:d:10.1007_s41669-022-00365-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-022-00365-z

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().